Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Boehringer Ingelheim Pharmaceuticals, Inc. v. United States Department of Health and Human Services et al
Case Number:
3:23-cv-01103
Court:
Nature of Suit:
Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision
Judge:
Firms
- Ballard Spahr
- Barclay Damon
- Covington & Burling
- Hagens Berman
- Koch Garg
- Koskoff Koskoff
- Lemberg Law
- Motley Rice
- Pullman & Comley
- Zuckerman Spaeder
Companies
- AARP Inc.
- American College of Physicians
- American Public Health Association
- American Society of Hematology
- Boehringer Ingelheim
- Boehringer Ingelheim Vetmedica Inc.
- Center for American Progress
- Center for Medicare Advocacy Inc.
- Democracy Forward Foundation
- Justice in Aging
- National Association for the Advancement of Colored People
- Public Citizen Inc.
Government Agencies
Sectors & Industries:
-
December 21, 2023
HHS Seeks Early Win Defending Medicare Drug Price Program
Boehringer Ingelheim and other drugmakers are free to take their business elsewhere if they object to the new Medicare price negotiation program, the federal government has said, urging a judge to reject the company's claims of constitutional violations.
-
October 06, 2023
Mapping Big Pharma's Blitz On Medicare Drug Price Talks
Lawsuits from Big Pharma and big business challenging Medicare's new power to negotiate drug prices are hurtling toward pivotal tests of lofty legal theories and the Biden administration's creative efforts to save its signature health care accomplishment. Here, Law360 explores the litigation landscape in a detailed map that will be updated as the saga evolves.
-
September 28, 2023
Boehringer Bemoans Medicare Drug Price Talks As 'A Sham'
Boehringer Ingelheim Pharmaceuticals Inc. slammed the new Medicare drug price negotiation program in a Connecticut federal court filing as a "sham from beginning to end," even as it indicated Thursday that it will engage with federal officials.
-
September 01, 2023
Novartis Joins Legal Fray After Price Negotiation List Unveiled
Novartis Pharmaceuticals Corp. on Friday joined the growing list of pharmaceutical companies challenging the Inflation Reduction Act, filing suit in New Jersey federal court just days after the Biden administration revealed the list of drugs in the inaugural round of Medicare price negotiations.
-
August 21, 2023
Boehringer Challenges Medicare Drug Price Negotiation Law
Boehringer Ingelheim Pharmaceuticals Inc. has filed another in a string of constitutional challenges to the Inflation Reduction Act, arguing that the U.S. Department of Health and Human Services is derailing drug research and innovation by taking property without due process protections as part of a scheme to cut drug prices.